These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 27720325)

  • 1. Novel approach of fragment-based lead discovery applied to renin inhibitors.
    Tawada M; Suzuki S; Imaeda Y; Oki H; Snell G; Behnke CA; Kondo M; Tarui N; Tanaka T; Kuroita T; Tomimoto M
    Bioorg Med Chem; 2016 Nov; 24(22):6066-6074. PubMed ID: 27720325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin.
    Rahuel J; Rasetti V; Maibaum J; Rüeger H; Göschke R; Cohen NC; Stutz S; Cumin F; Fuhrer W; Wood JM; Grütter MG
    Chem Biol; 2000 Jul; 7(7):493-504. PubMed ID: 10903938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design of a new series of N-(piperidin-3-yl)pyrimidine-5-carboxamides as renin inhibitors.
    Imaeda Y; Tawada M; Suzuki S; Tomimoto M; Kondo M; Tarui N; Sanada T; Kanagawa R; Snell G; Behnke CA; Kubo K; Kuroita T
    Bioorg Med Chem; 2016 Nov; 24(22):5771-5780. PubMed ID: 27687967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery of novel potent trans-3,4-disubstituted pyrrolidine inhibitors of the human aspartic protease renin from in silico three-dimensional (3D) pharmacophore searches.
    Lorthiois E; Breitenstein W; Cumin F; Ehrhardt C; Francotte E; Jacoby E; Ostermann N; Sellner H; Kosaka T; Webb RL; Rigel DF; Hassiepen U; Richert P; Wagner T; Maibaum J
    J Med Chem; 2013 Mar; 56(6):2207-17. PubMed ID: 23425156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel class of oral direct renin inhibitors: highly potent 3,5-disubstituted piperidines bearing a tricyclic p3-p1 pharmacophore.
    Ostermann N; Ruedisser S; Ehrhardt C; Breitenstein W; Marzinzik A; Jacoby E; Vangrevelinghe E; Ottl J; Klumpp M; Hartwieg JC; Cumin F; Hassiepen U; Trappe J; Sedrani R; Geisse S; Gerhartz B; Richert P; Francotte E; Wagner T; Krömer M; Kosaka T; Webb RL; Rigel DF; Maibaum J; Baeschlin DK
    J Med Chem; 2013 Mar; 56(6):2196-206. PubMed ID: 23360239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease: identification and development of β-secretase (BACE-1) binding fragments and inhibitors by dynamic ligation screening (DLS).
    Fernández-Bachiller MI; Horatscheck A; Lisurek M; Rademann J
    ChemMedChem; 2013 Jul; 8(7):1041-56. PubMed ID: 23757181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fragment Linking and Optimization of Inhibitors of the Aspartic Protease Endothiapepsin: Fragment-Based Drug Design Facilitated by Dynamic Combinatorial Chemistry.
    Mondal M; Radeva N; Fanlo-Virgós H; Otto S; Klebe G; Hirsch AK
    Angew Chem Int Ed Engl; 2016 Aug; 55(32):9422-6. PubMed ID: 27400756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of benzimidazole derivatives as orally active renin inhibitors: Optimization of 3,5-disubstituted piperidine to improve pharmacokinetic profile.
    Tokuhara H; Imaeda Y; Fukase Y; Iwanaga K; Taya N; Watanabe K; Kanagawa R; Matsuda K; Kajimoto Y; Kusumoto K; Kondo M; Snell G; Behnke CA; Kuroita T
    Bioorg Med Chem; 2018 Jul; 26(12):3261-3286. PubMed ID: 29754833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
    Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
    Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design technology contour and its application to the design of renin inhibitors.
    Ishchenko A; Liu Z; Lindblom P; Wu G; Jim KC; Gregg RD; Claremon DA; Singh SB
    J Chem Inf Model; 2012 Aug; 52(8):2089-97. PubMed ID: 22805048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tracing binding modes in hit-to-lead optimization: chameleon-like poses of aspartic protease inhibitors.
    Kuhnert M; Köster H; Bartholomäus R; Park AY; Shahim A; Heine A; Steuber H; Klebe G; Diederich WE
    Angew Chem Int Ed Engl; 2015 Feb; 54(9):2849-53. PubMed ID: 25630461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of potent macrocyclic renin inhibitors.
    Sund C; Belda O; Wiktelius D; Sahlberg C; Vrang L; Sedig S; Hamelink E; Henderson I; Agback T; Jansson K; Borkakoti N; Derbyshire D; Eneroth A; Samuelsson B
    Bioorg Med Chem Lett; 2011 Jan; 21(1):358-62. PubMed ID: 21112780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment-based lead discovery: screening and optimizing fragments for thermolysin inhibition.
    Englert L; Silber K; Steuber H; Brass S; Over B; Gerber HD; Heine A; Diederich WE; Klebe G
    ChemMedChem; 2010 Jun; 5(6):930-40. PubMed ID: 20394106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of highly potent renin inhibitors potentially interacting with the S3' subsite of renin.
    Sun X; Wen X; Chen YY; Shi C; Gao C; Wu Y; Wang LJ; Yang XH; Sun H
    Eur J Med Chem; 2015 Oct; 103():269-88. PubMed ID: 26363506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: prime site exploration using an amino linker.
    Lorthiois E; Cumin F; Ehrhardt C; Kosaka T; Sellner H; Ostermann N; Francotte E; Wagner T; Maibaum J
    Bioorg Med Chem Lett; 2015 Apr; 25(8):1782-1786. PubMed ID: 25782742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of 5,5'-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors.
    Malamas MS; Erdei J; Gunawan I; Turner J; Hu Y; Wagner E; Fan K; Chopra R; Olland A; Bard J; Jacobsen S; Magolda RL; Pangalos M; Robichaud AJ
    J Med Chem; 2010 Feb; 53(3):1146-58. PubMed ID: 19968289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragment-based lead discovery to identify novel inhibitors that target the ATP binding site of pyruvate dehydrogenase kinases.
    Akaki T; Bessho Y; Ito T; Fujioka S; Ubukata M; Mori G; Yamanaka K; Orita T; Doi S; Iwanaga T; Ikegashira K; Hantani Y; Nakanishi I; Adachi T
    Bioorg Med Chem; 2021 Aug; 44():116283. PubMed ID: 34274549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors.
    Wang YS; Strickland C; Voigt JH; Kennedy ME; Beyer BM; Senior MM; Smith EM; Nechuta TL; Madison VS; Czarniecki M; McKittrick BA; Stamford AW; Parker EM; Hunter JC; Greenlee WJ; Wyss DF
    J Med Chem; 2010 Feb; 53(3):942-50. PubMed ID: 20043700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragment-assisted hit investigation involving integrated HTS and fragment screening: Application to the identification of phosphodiesterase 10A (PDE10A) inhibitors.
    Varnes JG; Geschwindner S; Holmquist CR; Forst J; Wang X; Dekker N; Scott CW; Tian G; Wood MW; Albert JS
    Bioorg Med Chem Lett; 2016 Jan; 26(1):197-202. PubMed ID: 26597534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: prime site exploration using an oxygen linker.
    Sellner H; Cottens S; Cumin F; Ehrhardt C; Kosaka T; Lorthiois E; Ostermann N; Webb RL; Rigel DF; Wagner T; Maibaum J
    Bioorg Med Chem Lett; 2015 Apr; 25(8):1787-1791. PubMed ID: 25754490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.